Get the Stockscreener App
6.39
6.50%
0.39
After Hours:
6.39
Adaptive Biotechnologies Corp stock is traded at $6.39, with a volume of 1.48M.
It is up +6.50% in the last 24 hours and up +44.57% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$6.00
Open:
$5.84
24h Volume:
1.48M
Relative Volume:
1.22
Market Cap:
$943.03M
Revenue:
$170.28M
Net Income/Loss:
$-225.25M
P/E Ratio:
-4.8045
EPS:
-1.33
Net Cash Flow:
$-167.02M
1W Performance:
+1.43%
1M Performance:
+44.57%
6M Performance:
+99.69%
1Y Performance:
+34.81%
1-Day Range:
$5.84
$6.505
1-Week Range:
$5.805
$6.93
52-Week Range:
$2.28
$7.0665
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
6.39 | 943.03M | 170.28M | -225.25M | -167.02M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
BTIG Research Raises Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $9.00 - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6%What's Next? - MarketBeat
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year? - Yahoo Finance
Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
ADPT stock touches 52-week high at $6.71 amid robust gains By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $6.71 amid robust gains - Investing.com
Jacobs Levy Equity Management Inc. Makes New $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Point72 Asset Management L.P. Makes New $2.54 Million Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Pier Capital LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions - Yahoo Finance
ADPT (Adaptive Biotechnologies) 10-Year Sortino Ratio : N/A (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) 1-Year Sortino Ratio : 1.18 (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Adaptive Biotechnologies (STU:1HM) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Matrix Capital Management Company LP Sells 10,922,590 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Earnings Yield (Joel Gre - GuruFocus.com
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Short Interest Down 8.5% in November - MarketBeat
Adaptive Biotechnologies (STU:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies (STU:1HM) EPS (Diluted) : €-1.23 (TTM As of Sep. 2024) - GuruFocus.com
Cerity Partners LLC Boosts Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Rubric Capital Management LP Raises Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Massachusetts Financial Services Co. MA Lowers Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Benzinga
Millrace Asset Group Inc. Takes $1.40 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Adaptive Biotechnologies (NASDAQ:ADPT) Financial Survey - Defense World
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares - Investing.com India
Head to Head Comparison: Adaptive Biotechnologies (NASDAQ:ADPT) and Ginkgo Bioworks (NYSE:DNA) - Defense World
Adaptive Biotechnologies Corp: Is ADPT Stock Worth Buying? - Stocks Register
Short Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Declines By 5.5% - Defense World
William Blair Has Bullish Forecast for ADPT FY2024 Earnings - MarketBeat
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Decrease in Short Interest - MarketBeat
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know - Yahoo Finance
Rubric Capital Management LP's Strategic Acquisition in Adaptive Biotechnologies Corp - GuruFocus.com
Matrix Capital Management Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 12.7% Following Analyst Upgrade - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst Upgrade - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00 - MarketBeat
ADPT (Adaptive Biotechnologies) Cash From Other Investing A - GuruFocus.com
Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Earnings call: Adaptive Biotechnologies posts robust MRD revenue growth - Investing.com
ARK Investment Management LLC Buys 189,134 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highl - GuruFocus.com
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):